Opus Genetics (IRD) Operating Expenses (2010 - 2026)

Opus Genetics (IRD) has 17 years of Operating Expenses data on file, last reported at $16.5 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 15.54% year-over-year to $16.5 million in Q1 2026; TTM through Mar 2026 was $55.0 million, a 29.42% decrease from a year earlier, with the FY2025 full-year figure at $52.8 million, down 27.74% from the prior year.
• Operating Expenses for Q1 2026 stood at $16.5 million, up from $15.3 million in the prior quarter.
• Over the last five years, Operating Expenses for IRD reached as high as $42.3 million in Q4 2024 and fell as low as $4.5 million in Q3 2022.
• Historically, Operating Expenses has averaged $11.4 million across 5 years, with a median of $9.4 million in 2024.
• Across the five-year window, Operating Expenses jumped 494.54% in 2024 and plunged 63.81% in 2025, its largest moves.
• Year by year, Operating Expenses stood at $5.6 million in 2022, then climbed by 26.24% to $7.1 million in 2023, then soared by 494.54% to $42.3 million in 2024, then sank by 63.81% to $15.3 million in 2025, then gained by 7.85% to $16.5 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $16.5 million in Q1 2026, $15.3 million in Q4 2025, and $11.4 million in Q3 2025.